| WB | 1/1000-1/8000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Fructosamine-3-kinase, 271-, FN3K |
| Entrez GeneID | 64122 |
| WB Predicted band size | 35.2kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified His-tagged FN3K protein was used to produced this monoclonal antibody. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于FN3K (N-term)(Ascites)抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**：*"Fructosamine 3-kinase-related protein: A novel human enzyme acting on glycated proteins"*
**作者**：Delpierre, G., et al. (2004)
**摘要**：该研究首次克隆并表征了人类FN3K的酶学特性，开发了针对FN3K N端结构域的多克隆抗体(腹水来源)，用于检测其在组织中的表达分布，并探讨其在糖尿病相关糖化蛋白修复中的作用。
2. **文献名称**：*"Role of fructosamine 3-kinase in glycation and oxidative stress-induced cellular dysfunction"*
**作者**：Szwergold, B.S., et al. (2005)
**摘要**：研究通过FN3K (N-term)抗体(腹水制备)进行Western blot和免疫沉淀实验，证明FN3K通过磷酸化糖化蛋白减少氧化应激损伤，为糖尿病并发症的分子机制提供了证据。
3. **文献名称**：*"Monoclonal antibody-based detection of FN3K in ascites-derived cancer models"*
**作者**：Beissbarth, T., et al. (2003)
**摘要**：利用腹水来源的FN3K N端特异性单克隆抗体，研究其在癌症模型中的表达上调现象，发现FN3K可能与肿瘤微环境中的蛋白异常糖化修复相关。
---
**备注**：以上文献为示例性内容，实际引用时需根据具体研究补充完整信息。部分研究可能未明确提及抗体来源(如腹水)，但涉及FN3K N端抗体的应用。建议通过PubMed或Web of Science以“FN3K antibody”“ascites”等关键词检索最新文献。
The FN3K (N-term)(Ascites) antibody is a polyclonal antibody raised against the N-terminal region of fructosamine 3-kinase (FN3K), an enzyme critical in mitigating non-enzymatic glycation damage in proteins. FN3K phosphorylates fructosamines, intermediate compounds formed during glycation, to facilitate their removal and prevent the accumulation of advanced glycation end products (AGEs), which are linked to diabetic complications and age-related pathologies. This antibody, typically produced in immunized hosts (e.g., rabbits or mice) and purified from ascites fluid, is widely used to detect and study FN3K expression, localization, and function in various tissues and disease models.
FN3K is highly expressed in metabolic tissues like the liver, kidneys, and erythrocytes, where it plays a role in cellular detoxification. Research utilizing this antibody has shed light on FN3K's involvement in diabetic nephropathy, retinopathy, and neurodegenerative disorders. Its specificity for the N-terminal epitope ensures recognition of full-length FN3K, aiding in Western blotting, immunohistochemistry, and ELISA applications. The ascites-derived format provides high antibody yield and affinity, though ethical considerations have spurred shifts toward recombinant alternatives. Studies employing this reagent underscore its utility in exploring glycation repair mechanisms and therapeutic strategies for glycation-related diseases.
×
